CLDN1 and colorectal carcinoma: To test this hypothesis, we assessed the effect of single-agents used in the FDA-approved FOLFOX or FOLFIRI combinations for CRC (5-FU, irinotecan, and oxaliplatin) on CLDN1 expression in the SW620 CRC cell line.